PAR paradigm biopharmaceuticals limited..

Ann: POSITIVE TOP-LINE RESULTS FROM PRECLINICAL STUDY IN ARDS, page-28

  1. 1,216 Posts.
    lightbulb Created with Sketch. 1375
    Interesting set of results.

    The immune cell infiltrates are reduced in PPS treated mice by around 20%, which is ideal since this will allow the immune system to continue fighting the virus infection while simultaneously reducing the damage caused by the immune response. The reduction in immune cell infiltrates appears to be linked to the reduced collagen deposition observed in the lungs of mice given PPS.

    I'm not convinced by the fibrosis story the PAR management team are trying to sell here, but what is clear is PPS has a noticable impact on the inflammatory response - there are several indicators that support PPS reduces the acute inflammatory response, including biomarker data.

    The fact that very little weight loss was observed for the mice given PPS indicates that they only experienced mild symptoms associated with influenza A infection, while those that received saline experienced more severe symptoms.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
44.0¢
Change
0.020(4.76%)
Mkt cap ! $178.8M
Open High Low Value Volume
42.5¢ 46.0¢ 42.0¢ $347.2K 796.8K

Buyers (Bids)

No. Vol. Price($)
3 25262 44.0¢
 

Sellers (Offers)

Price($) Vol. No.
44.5¢ 228 1
View Market Depth
Last trade - 16.10pm 15/07/2025 (20 minute delay) ?
PAR (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.